Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment

References

Page 1

	Year	Citations
A New Mouse Myeloma Cell Line that Has Lost Immunoglobulin Expression but Permits the Construction of Antibody-Secreting Hybrid Cell Lines John F. Kearney, Andreas Radbruch, B Liesegang, The Journal of Immunology	1979	1.9K
Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors Hajime Karasuyama, Fritz Melchers European Journal of Immunology	1988	1.1K
Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients Steven A. Rosenberg, Michael T. Lotze, James Chih‐Hsin Yang, Annals of Surgery Alpha InterferonTumor ImmunologyCancer ImmunosurveillanceMedicineCancer Management	1989	1K
Passive immunity in mice against C57BL leukosis E.L. 4 by means of iso-immune serum. P. A. Gorer, D. Bernard Amos PubMed Clinical ImmunologyImmunohematologyLaboratory ImmunologyImmunologyInnate Immunity	1956	162
Immunotheraphy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2 J Bubeník, Jana Šímová, T Jandlová Immunology Letters Local AdministrationLymphoid NeoplasiaCancer ImmunosurveillanceIl-2 CdnaImmunology	1990	85
Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice J Bubeník, Nikolai N. Voitenok, J. Kieler, Immunology Letters Local AdministrationTumor BiologyCytokineImmunologyCell Proliferation	1988	80
Retroviral gene transfer induced constitutive expression of interleukin- 2 or interferon-gamma in irradiated human melanoma cells Bernd Gänsbacher, Karen S. Zier, Kathy A. Cronin, Blood	1992	79
Tumour inhibitory effects of TCGF/IL-2/-containing preparations J. Buben�k, M. Indrov�, Peter Perlmann, Cancer Immunology Immunotherapy Tumor BiologyImmunologyTumour Inhibitory EffectsAnti-cancer AgentMedicine	1985	33
Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide. K Naito, N R Pellis, B D Kahan PubMed Bolus InjectionTransplantation MedicineImmunologyContinuous AdministrationMetronomic Chemotherapy	1988	27
Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2. Daniel A. Vallera, Patricia A. Taylor, Sharon L. Aukerman, PubMed Continuous Subcutaneous CoadministrationImmunologyImmunoeditingImmunologic MechanismImmunotherapy	1993	17

Page 1